Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study

FDA and Bristol-Myers Squibb went to great lengths to ensure that interim overall survival data from a first-line study of Yervoy (ipilimumab) could be reviewed by the agency in a manner that maintained the trial’s blind.